newsfilter
← Earnings
Earnings Releases·

Trevi Therapeutics — Third Quarter 2026 Earnings Summary

Trevi Therapeutics initiated its Phase 3 OCEAN-2 trial for IPF-related chronic cough in the third quarter of 2026, with both OCEAN trials currently actively recruiting patients. The company received FDA alignment on its non-IPF ILD-related chronic cough program and plans to start a Phase 2 dose-ranging trial in the first quarter of 2027. Financially, the company reported a net loss of $21.5 million for the quarter ended September 30, 2026, while maintaining $299.4 million in cash and marketable securities to fund operations through 2030.

Company
TREVI THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology